Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab after neoadjuvant chemo-immunotherapy and surgery for resectable non-small cell lung cancer
ACTRN12624001373561Phase 3Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Mar 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant durvalumab with Observation (2 arms). Primary endpoint: Disease-free survival in patients without pathological complete response. Started Mar 2025; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12624001373561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001373561.